PRESS RELEASE
February 17, 2015

For comment/interviews with Novotech contact:
Digital Mantra Group
Australia: +61 2 8218 2144
USA: +1 650 7985238
Email: team@dmgpr.com

NOVOTECH LEADS THE FAST GROWING ASIA PACIFIC CLINICAL RESEARCH SECTOR WITH ANOTHER FROST & SULLIVAN "CRO BEST PRACTICE AWARD"

Sydney, Australia, February 17, 2015 | Novotech, the largest Australia-based clinical CRO with offices throughout the Asia region, has just been awarded the *CRO Best Practice Award* for the third time in recent years by Frost & Sullivan.

"Novotech has a reputation for delivering services and information that meets/exceeds the quality standards demanded by customers, doctors, patients and regulatory authorities," said Sanjeev Kumar, Analyst Asia Pacific Healthcare Practice Frost & Sullivan.

"Novotech has proven its excellence in the Australia and Asia Pacific market by showing innovation and strong growth performance," Mr Kumar said.

"Novotech provides access to the most dynamic and fast growing clinical research hubs in the region."

"The company has exhibited a unique flexibility in terms of handling small to very large projects. With use of technologies such as Medidata RAVE for Electronic Data Capture, Oracle Empirica Trace for Pharmacovigilance and safety management, Oracle Siebel for Clinical Trial Management System etc., Novotech has shown its commitment to provide fast and accurate service to its clients.

Also, the company has created a strong brand perception in the minds of its customers, which has resulted in several long-term partnerships and alliances."

Novotech CEO Alek Safarian said the company was honoured to be recognised once again with this prestigious award.

He said the Asia Pacific is the fastest growing region for clinical research and Novotech, established in 1996, is clearly a leader in the region providing a full suite of research and regulatory services, in emerging markets with a population base of over 3 billion people.

He said feedback and demand from Novotech's USA and EU biotech and pharma sponsors is the driver for continued expansion of services in the Asia Pacific region.

Novotech has been actively involved in hundreds of drug development programs for US and EU registration since 1996.

Award ceremony image

CAPTION: Lynda Shelly Executive Director, Clinical Operations at Novotech accepting the award from the F&S Australia Managing Director, Mark Dougan.

Recent news: http://www.novotech-cro.com/news-events
- Novotech moves offices in Hong Kong

- Novotech opens China office

- Novotech appoints Dr John Moller as Asia COO based in Singapore

About Novotech www.novotech-cro.com
Established in 1996 and headquartered in Sydney, Novotech has a strong presence in the Asia Pacific region, running clinical trials in all key regional markets including China, India, Australia, Taiwan and Korea. Novotech also has offices in South Africa.

Novotech also has worldwide reach through the company's network of strategic partners. Novotech - described by Frost & Sullivan as the best in its industry class for Australia-based CROs and recipient of the **ARCS** ANZ Clinical Trials award in 2013 for "Best **CRO**" - brings its global reputation for high quality service and regional expertise to the high-growth Asia Pacific area. For more information, please visit www.novotech-cro.com.

Novotech provides the following clinical development services across all clinical trial phases and therapeutic areas including Feasibility assessments; Ethics Committee and submissions, clinical monitoring, data management, statistical analysis, report write-up to ICH requirements, project management and vendor management.

About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants.

For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community.